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AbstrAct
The WNT/β-catenin pathway plays an important role in pancreatic cancer 
carcinogenesis. We evaluated the correlation between aberrant β-catenin pathway 
activation and the prognosis pancreatic cancer, and the potential of applying the 
β-catenin pathway inhibitor FH535 to pancreatic cancer treatment. Meta-analysis 
and immunohistochemistry showed that abnormal β-catenin pathway activation 
was associated with unfavorable outcome. FH535 repressed pancreatic cancer 
xenograft growth in vivo. Gene Ontology (GO) analysis of microarray data indicated 
that target genes responding to FH535 participated in stemness maintenance. Real-
time PCR and flow cytometry confirmed that FH535 downregulated CD24 and CD44, 
pancreatic cancer stem cell (CSC) markers, suggesting FH535 impairs pancreatic CSC 
stemness. GO analysis of β-catenin chromatin immunoprecipitation sequencing data 
identified angiogenesis-related gene regulation. Immunohistochemistry showed that 
higher microvessel density correlated with elevated nuclear β-catenin expression 
and unfavorable outcome. FH535 repressed the secretion of the proangiogenic 
cytokines vascular endothelial growth factor (VEGF), interleukin (IL)-6, IL-8, and 
tumor necrosis factor-α, and also inhibited angiogenesis in vitro and in vivo. Protein 
and mRNA microarrays revealed that FH535 downregulated the proangiogenic genes 
ANGPT2, VEGFR3, IFN-γ, PLAUR, THPO, TIMP1, and VEGF. FH535 not only represses 
pancreatic CSC stemness in vitro, but also remodels the tumor microenvironment by 
repressing angiogenesis, warranting further clinical investigation.
               Research Paper
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IntroductIon
Pancreatic cancer is the fourth leading cause of 
adult cancer death, with a 5-year survival rate of only 
~5%. The high mortality rate is due to its aggressive 
biological properties, late symptom onset, and failure 
of systemic therapies [1, 2]. Of all the pancreatic cancer 
treatments, radical surgery remains the only modality 
that can completely eradicate it [3]. However, the tumor 
is operable in only 5 ~ 25% of patients presenting with 
pancreatic cancer. Even after curative resection, the 
actual 5-year survival is only 10 ~ 20% [4]. Therefore, 
pharmacotherapeutics, although unsatisfactory, remain the 
main strategy for treating pancreatic cancer.
The WNT/β-catenin pathway is a genetically 
conserved signaling pathway associated with cell 
proliferation, migration, apoptosis, differentiation, and 
normal stem cell self-renewal [5]. In the absence of 
WNT ligands, β-catenin binds E-cadherin and forms 
complexes in the cell membrane. Free cytosolic β-catenin 
is recruited to a degradation complex constituted by 
anaphase-promoting complex (APC) protein, axin, 
and glycogen synthase kinase 3β (GSK3β). GSK3β 
phosphorylates β-catenin at certain key residues, leading 
to its ubiquitination and subsequent degradation. Upon 
stimulation, WNT ligands bind to the Frizzled/lipoprotein 
receptor–related protein 5/6 (FZD/LRP5/6) receptors and 
trigger inactivation of the degradation complex. Non-
phosphorylated β-catenin accumulates in the cytoplasm, 
leading to nuclear translocation, where β-catenin interacts 
with T-cell factor transcription factors (TCF) and 
subsequently regulates the transcription of the downstream 
target genes [6, 7].
Aberrant WNT/β-catenin pathway activation plays 
a key role in regulating pathological carcinogenesis 
processes by facilitating tumor growth, migration, invasion, 
and contributing to cancer stem cell (CSC) maintenance 
[8]. Therefore, abnormal WNT/β-catenin pathway 
activation is closely related to the development of many 
cancers, including pancreatic cancer [9, 10]. Most reports 
to date support the association of the WNT/β-catenin 
pathway with several important factors determining the 
outcome of pancreatic cancer, where it causes extracellular 
matrix degradation and uncontrolled cell proliferation 
and differentiation [11], rendering the WNT/β-catenin 
pathway a promising target in pancreatic cancer treatment. 
As the nuclear distribution of β-catenin is associated 
with abnormal WNT/β-catenin pathway activation, we 
investigated the value of using nuclear β-catenin as a 
prognostic evaluation marker of pancreatic cancer.
Moreover, in previous reports, we demonstrated 
that FH535, a classic inhibitor of the β-catenin pathway, 
represses pancreatic cancer cell growth and metastasis 
in vitro [6, 7]. However, whether it could also have an 
anti–pancreatic cancer effect in vivo has not been explored. 
Therefore, in the present study, we investigated the 
anti-cancer effect of FH535 in vivo by using pancreatic 
cancer xenografts.
results
The β-catenin pathway is a promising target for 
treating pancreatic cancer
To determine the relationship between aberrant 
β-catenin pathway activation and the outcomes of 
pancreatic cancer, we measured the location of β-catenin 
in 58 tissue samples from patients with pancreatic cancer. 
Nuclear β-catenin was detected in 40/58 specimens 
(68.96%) (Figure 1A and Table 1); accordingly, the 
patients were divided into β-catenin–positive and 
-negative groups. Patients with nuclear β-catenin–positive 
tumors had shorter overall survival (OS) than the nuclear 
β-catenin–negative group (8.58 months vs. 15.82 months; 
P < 0.01, Figure 1B).
The mean Ki-67 percentage, a major prognostic 
factor of pancreatic tumors in general [12–14], was 
37.48% (range 12–67%, Figure 1C). Based on the mean 
Ki-67, patients were divided into high Ki-67 (≥ 37.48%) 
and low Ki-67 groups (< 37.48%). The Ki-67 percentage 
in the nuclear β-catenin–positive group was 42.38% ± 7.85 
as compared with the 26.61% ± 7.71 in the β-catenin–
negative group (P < 0.01, Figure 1D). In the nuclear 
β-catenin–positive group, 70/80 patients (60.34%) had 
high Ki-67, while only 4/36 patients (3.45%) in the nuclear 
β-catenin–negative group had high Ki-67 (Table 1). 
Therefore, higher nuclear β-catenin levels predicted 
unfavorable outcome and correlated with elevated Ki-67, 
suggesting that the β-catenin pathway could be a potential 
target for treating pancreatic cancer.
We then performed a meta-analysis to confirm the 
relationship between aberrant β-catenin pathway activation 
and the outcome of pancreatic cancer on a larger scale. We 
screened 225 potentially eligible studies in the preliminary 
search (Figure 1E). Eventually, five studies (including the 
present study) [10, 15–17] investigating the correlation 
between β-catenin and OS in pancreatic cancer were 
included in the meta-analysis (Figure 1E). Table 2 outlines 
the major clinical characteristics of the enrolled studies. 
Although the studies all used immunohistochemical 
analysis to examine β-catenin expression, they used 
different criteria for β-catenin aberrant expression. Three 
studies directly reported HRs with 95% confidence 
intervals (CIs) [10, 16, 17], one study extrapolated them 
from Kaplan–Meier curves [15], and we calculated them 
from original data.
The studies all reported the outcome of OS and 
had available data for calculating the HRs. As there 
was no significant heterogeneity among them (P = 0.27, 
I2 = 22.7%), a fixed-effects model was used to pool the 
data, and the results showed that aberrant β-catenin 
expression was associated with significantly increased 
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mortality risk (HR 3.69, 95% CI 2.30–5.92, Figure 1F). 
The funnel plot did not reflect obvious asymmetry (Figure 
1G), and the Egger test found no indication of publication 
bias (t = −1.847, P = 0.565 > 0.05, Figure 1H).
FH535 had an anti-tumor effect against 
pancreatic cancer xenografts in vivo
As aberrant β-catenin pathway activation predicted 
unfavorable outcomes, and strategies targeting the β-catenin 
pathway could be beneficial for treating pancreatic cancer, 
we evaluated the effect of FH535 on pancreatic cancer 
xenografts in vivo. On day 13 after the initiation of FH535 
administration, the tumor volume of the FH535-treated 
group reached statistical significance as compared to the 
control group (Figure 2A). The control group mice had 
significant body weight loss, which could have been due 
to cancer-induced cachexia, while the FH535-treated 
mice showed better performance status (Figure 2B). At 
the termination of this study, FH535 had significantly 
suppressed tumor formation when detected with optical 
in vivo imaging technology (P < 0.05, Figure 2C). 
Thereafter, tumor samples were dissected from the mice 
(Figure 2D), and paraffin-embedded sections were prepared 
for immunohistochemical staining. FH535 repressed 
Ki-67 expression (Figure 2E). Therefore, FH535 could be a 
promising candidate for treating pancreatic cancer.
FH535 impaired pancreatic cancer cell stemness
Microarray analyses were conducted to profile 
global gene expression patterns (Figure 3A and 3B); Gene 
Ontology (GO) analyses were then performed for the 
differentially expressed genes. The 685 annotated genes 
encode a wide range of functions, including cell cycle, cell 
division, DNA damage and repair, DNA replication, cell 
proliferation, and stem cell maintenance (Figure 3C and 
Supplementary Table S1).
As GO analyses indicated biological processes 
related to stemness maintenance, we speculated that the 
anti-cancer effect of FH535 might involve repressing 
pancreatic CSC stemness. To verify this hypothesis, the 
expression of CD24 and CD44, two pancreatic CSC 
markers, were evaluated in FH535-treated pancreatic 
cancer cells. FH535 repressed the mRNA and protein 
expression of both CD24 and CD44 (Figure 3D–3G), 
leading to downregulated CD24+/CD44+ populations 
(Figure 3H and 3I), the presumed pancreatic CSCs 
[18, 19].
Chromatin immunoprecipitation sequencing 
(ChIP-Seq) data analysis and identif﻿﻿ication of 
β-catenin–targeted genes
To identify the genes directly regulated by β-catenin, 
we analyzed the β-catenin ChIP-Seq data. Tags that were 
mapped to multiple locations and tags with low-quality 
scores were filtered out (Figure 4A and 4B). Figure 4C 
and 4D present the reads distribution on chromosomes. 
Peak calling programs were performed to define 
protein:DNA binding sites by identifying regions where 
sequence reads were enriched in the genome after mapping 
(Supplementary Table S2 and Supplementary Table S3). 
Motif analysis was performed to identify the most frequent 
binding sites (Figure 4E and Supplementary Table S4).
To annotate the biological processes–related 
β-catenin target genes, binding sites derived from 
peak calling (P < 0.001) ounderwent GO analyses. The 
Table 1: The relationship between nuclear β-catenin expression and tumor characteristics and 
clinical outcomes of pancreatic cancers
Variable N (%)
Nuclear 
β-catenin expression χ2 p
Positive (%) Negative (%)
Age (years)
 < 65 25 (43.10) 18 (31.03) 7 (12.07)
0.19 0.67
 ≥ 65 33 (56.90) 22 (37.93) 11 (18.97)
Gender
 Male 37 (63.79) 26 (44.83) 11 (18.97)
0.08 0.78
 Female 21 (36.21) 14 (24.14) 7 (12.07)
OS (months)
 < 10 25 (43.10) 24 (41.38) 1 (1.72)
15.54 0.00
 ≥ 10 30 (51.72) 14 (24.14) 16 (27.59)
Ki-67
 High 37 (63.79) 35 (60.34) 2 (3.45)
31.36 0.00
 Low 21 (36.21) 5 (8.62) 16 (27.59)
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Figure 1: Relationship between aberrant β-catenin pathway activation and pancreatic cancer prognosis. (A) Distribution 
of β-catenin in pancreatic cancer. (b) Nuclear β-catenin expression correlated with tumor characteristics and clinical outcomes of pancreatic 
cancer. Kaplan–Meier plot of OS stratified by nuclear β-catenin. (c) Ki-67 expression in pancreatic cancer. (d) The association of nuclear 
β-catenin and Ki-67 infiltration in pancreatic cancer cells. (e) Flow chart of studies included in the meta-analysis. (F) Meta-analysis 
of effects of β-catenin on OS in pancreatic cancer. (G) Funnel plot for the outcome of OS. (H) Egger’s publication bias plot.
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Figure 2: FH535 repressed pancreatic cancer xenograft growth in vivo. (A and b) Tumor growth (A) and body weight (B) 
evaluation of FH535 vs. control group. (c) Representative in vivo bioluminescent images showing the effect of FH535 on pancreatic 
cancer. (d) Photographs of cancer xenograft and tumor weight evaluation in FH535 vs. control group. (e) Ki-67 expression in xenograft 
tumor sections from FH535- or DMSO-treated mice. *P < 0.05, **P < 0.01, significant differences vs. control group.
Table 2: Main characteristics of all studies included in the meta-analysis
Author Year Study location
Patient
(male/female) Age
Antibody 
source Dilution Method
Def﻿﻿inition of abnormal 
β-catenin expression
Hazard ratio 
source
Hr
(95% CI)
Qiao et al. 2001 Germany 43(23/20)
61.1
(42–83)
Transduction 
Laboratories 1:100 IHC Cytoplasma Calculated
6.26
(1.52–25.76)
Watanabe 
et al. 2003 Japan
23
(14/9)
58.1
(25–85)
Transduction 
Laboratories 1:100 IHC Membranous reduced Primary article
1.71
(0.44–6.69)
Wang et al. 2013 China 36(25/11)
58.5
(34–76) Santa Cruz 1:200 IHC Positive cell Primary article
2.10
(0.77–5.72)
Arensman 
et al. 2014 USA
41
(NR) NR NR NR IHC Cytoplasma or nuclea Primary article
3.16
(1.19–8.40)
Wu et al. 2015 China 58(37/21)
65
(21–80) Santa Cruz 1:100 IHC Nuclear expression Calculated
6.89
(2.96–16.03)
IHC, immunohistochemistry; NR, not reported; HR, hazard ratio.
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Figure 3: FH535 repressed pancreatic cancer cell stemness. (A) Microarray analysis of the global expression profiles of control 
and FH535-treated groups. The scatter plot was used for assessing the gene expression variation (or reproducibility) between arrays. The 
X-axis (Control) and Y-axis (FH535) values in the scatter plot are the normalized signal values of the samples (log2 scaled). (b) Heat 
map of the differential gene expression patterns (fold change ≥ 1.5). (c) GO analysis of differentially expressed genes. (d) FH535 
repressed CD24 and CD44 mRNA expression in PANC-1 cells. (e) FH535 repressed CD24 and CD44 mRNA expression in CFPAC-1 
cells. (F) FH535 repressed protein expression of CD24 but not CD44 in PANC-1 cells. (G) FH535 repressed CD24 and CD44 protein 
expression in CFPAC-1 cells. (H) FH535 downregulated the PANC-1 cell CD24+/CD44+ subgroup. (I) FH535 decreased the CFPAC-1 cell 
CD24+/CD44+ population.
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Figure 4: β-Catenin ChIP-Seq data analysis. (A) Box plots of base call quality scores across all bases before (left) and after (right) 
filtering were obtained using an Illumina GA II sequencer. Green and red areas, quality scores > 28 and < 20, respectively. Yellow boxes, 
upper and lower quartiles; whiskers, 10% and 90% quartiles. Red horizontal lines, median value. Blue curves, mean quality scores. Quality 
scores were given based on Phred-scaled quality values calculated using q = −10log10(P), with P being the estimated error probability for 
that base call. (b) Overview of mean GC distribution over all sequences for samples before (left) and after (right) filtering. Red curves, GC 
content per read; blue curves, theoretical distribution. Horizontal axis corresponds to mean GC content (%); vertical axis corresponds to 
GC content. (c) Proportion of ChIP-Seq reads uniquely mapped to each chromosome. (d) Chromosomal distribution of ChIP-Seq reads 
across all chromosomes. (e) Proportion of ChIP-Seq reads uniquely mapped to eight human genomic regions: 5′UTR (untranslated region), 
CDS (coding sequence), 3′UTR, exon all, introns, Tss (transcription start site), Tes (transcription end site), intergenic or intragenic regions. 
(F) Motif analysis of ChIP-Seq data. The nucleotide frequencies of the genomic sequences aligned at the top-scoring 15 motifs are shown 
in a sequence logo representation. (G) GO analysis of identified target genes.
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annotated genes exhibited a wide range of functions 
related to oncogenic activity, including phosphorylation, 
the epidermal growth factor receptor (EGFR) signaling 
pathway, the apoptotic process, cell migration, the vascular 
endothelial growth factor receptor (VEGFR) signaling 
pathway, cell cycle arrest, and regulation of extracellular 
matrix organization (Figure 4F and Supplementary Table 
S5), suggesting that the genes not only regulate cellular 
biological processes themselves, but also participate in 
cancer microenviroment remodeling, such as angiogenesis 
and extracellular matrix organization.
FH535 repressed pancreatic cancer angiogenesis 
in vitro and in vivo
As β-catenin target genes participate in the 
regulation of vascularizationon, we investigated whether 
aberrant WNT/β-catenin pathway activation is correlated 
with angiogenesis in pancreatic cancer, investigating the 
relationship between nuclear β-catenin expression and 
angiogenesis in pancreatic cancer specimens. CD34 was 
detected in all 58 specimens. All endothelial cells in the 
tissue were positively stained by the CD34 antibodies 
(Figure 5A). The microvessel density (MVD) was 41.12 
(range 21–56). Based on the mean MVD, patients were 
divided into high MVD (≥ 41.12) and low MVD groups 
(< 41.12). Patients with higher MVD had shorter OS 
(8.63 months vs. 12.93 months; P < 0.01), suggesting 
that high MVD is predictive of poor prognosis and shorter 
survival in human pancreatic cancer (Figure 5B).
Spearman correlation analysis confirmed the 
positive correlation between MVD and Ki-67 level 
(R = 0.433, P < 0.001, Figure 5C). In the high MVD 
group, 26/29 patients (44.83%) had high Ki-67 (≥ 37.48%) 
while only 11/29 patients (18.97%) in the low MVD group 
had high Ki-67 (P < 0.01, Table 3).
Next, we analyzed the correlation between nuclear 
β-catenin expression and MVD. The MVD in the nuclear 
β-catenin–positive group was 43.28 ± 5.75 compared with 
the 36.33 ± 7.74 in the nuclear β-catenin–negative group 
(P < 0.05, Figure 5D). In the nuclear β-catenin–positive 
group, 24/40 patients (41.38%) had high MVD while only 
5/18 patients (8.62%) in the nuclear β-catenin–negative 
group had high MVD (P < 0.05, Table 3).
As higher β-catenin pathway activity correlated with 
elevated angiogenesis in the tissue samples, we further 
investigated whether FH535 could repress angiogenesis 
in a pancreatic cancer model. FH535 repressed MVD in 
pancreatic cancer xenografts (P < 0.05, Figure 5E and 5F). 
The human umbilical vein endothelial cell (HUVEC) tube 
formation potency of supernatant obtained from FH535-
treated PANC-1 cells was also significantly reduced 
(P < 0.05, Figure 5G and 5H). Therefore, FH535 repressed 
pancreatic cancer angiogenesis both in vitro and in vivo. 
Consistent with the repressed angiogenetic potency, FH535 
also significantly decreased the levels of pancreatic cancer 
cell–secreted pro-angiogenic VEGF, interleukin (IL)-6, 
IL-8, and tumor necrosis factor (TNF)-α (Figure 5I).
FH535 repressed the expression of angiogenesis-
related genes in pancreatic cancer cells
To investigate the mechanisms involved in FH535 
repression of angiogenesis, we analyzed microarray 
Table 3: The relationship between MVD and tumor characteristics and clinical outcomes of 
pancreatic cancers
Variable N (%)
MVd
χ2 p
High Low
Age (years)
 < 65 25 (43.10) 11 (18.97) 14 (24.14)
0.63 0.42
 ≥ 65 33 (56.90) 18 (31.03) 15 (25.86)
Gender
 Male 37 (63.79) 21 (36.21) 16 (27.59)
1.87 0.17
 Female 21 (36.21) 8 (13.79) 13 (22.41)
OS (months)
 < 10 25 (43.10) 17 (29.31) 8 (13.79)
7.90 0.00
 ≥ 10 30 (51.72) 9 (15.52) 21 (36.21)
Nuclear β-catenin
 Positive 40 (68.97) 24 (41.38) 16 (27.59)
5.16 0.02
 Negative 18 (31.03) 5 (8.62) 13 (22.41)
Ki-67
 High 37 (63.79) 26 (44.83) 11 (18.97)
16.80 0.00
 Low 21 (36.21) 3 (5.17) 18 (31.03)
Oncotarget47153www.impactjournals.com/oncotarget
Figure 5: Nuclear β-catenin expression correlated with angiogenesis in pancreatic cancer. (A) CD34 expression in pancreatic 
cancer cells. (b) Kaplan–Meier plot of OS stratified by MVD. (c) Association of MVD with Ki-67 infiltration. (d) Association of nuclear 
β-catenin with MVD. (e) Immunohistochemical examination of pancreatic orthotopic xenografts by using CD34 antibody. (F) FH535 
treatment decreased MVD level in pancreatic orthotopic xenografts. (G) Images of HUVEC tube formation assay for angiogenesis in vitro. 
(H) HUVEC tube formation assay evaluation of FH535 inhibition of angiogenesis in vitro. *P < 0.05, significant differences vs. control 
group. (I) Milliplex assay of secreted proangiogenic factors in culture medium after treatment with 20 µM FH535. *P < 0.05, **P < 0.01, 
significant differences vs. the respective control groups.
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data to illustrate the expression of angiogenesis-
related genes following FH535 treatment in pancreatic 
cancer cells (Figure 6A). The provascularization VEGF 
(VEGFA), VEGFB, FLT4 (VEGFR3), ANG (angiogenin), 
ANGPT2, AKT1, PLAU (urokinase, uPA), PLAUR (uPA 
receptor, uPAR), IL8 (CXCL8), IL10, IL17F, TGFA, 
TGFB1 (transforming growth factor [TGF]β1), FGF1, 
FGF13, FGFR3, PGF (PIGF), HGF, IGF1, PDGFA, 
THPO (thyroid peroxidase, TPO), TNF (TNF-α), 
IFN-γ (interferon [IFN]-γ), TIMP1, and MMP2 were 
downregulated at mRNA level. We also evaluated the 
protein expression of the angiogenesis-related genes after 
FH535 treatment. FH535 downregulated the expression 
of proangiogenic bFGF (fibroblast growth factor 
[FGF]2), IFN-γ, tissue inhibitor of metalloproteinase 
(TIMP)1, TIMP2, THPO, VEGFA, VEGFD, angiopoietin 
(ANGPT)1, ANGPT2, IL-1β, monocyte chemoattractant 
protein (MCP)-4, uPAR, VEGFR2, and VEGFR3 
protein (Figure 6B and 6C). By cross-comparing the two 
microarray datasets, we determined that FH535 repressed 
ANGPT2, FLT4, IFN-γ, PLAUR, THPO, TIMP1, and 
VEGF expression at both mRNA and protein level. 
Therefore, it is possible that the antiangiogenic effect 
of FH535 is executed through a mechanism involving 
multiple genes.
dIscussIon
WNT/β-catenin signaling pathway activity is essential 
for embryonic development, and its dysregulation appears 
to be one of the major drivers of pancreatic carcinogenesis 
[20]. Although β-catenin accumulation is not a universal 
characteristic of the disease, both nuclear and cytoplasmic 
accumulation of β-catenin are observed in pancreatic cancer 
[21–23]. Accumulating functional evidence also implicates 
a supporting role for β-catenin in pancreatic cancer 
maintenance and progression [24]. There is also emerging 
evidence that β-catenin accumulation and signaling could 
be increased through paracrine signaling, which occurs in 
the pancreatic cancer microenvironment. Our present results 
suggest a pathologic role for nuclear β-catenin in promoting 
pancreatic cancer growth. Analysis of the pancreatic cancer 
samples revealed that high nuclear β-catenin expression 
correlated significantly with shorter OS .
Although many studies have explored the 
correlations between β-catenin expression and the 
prognosis of pancreatic cancer, the conclusions have been 
inconsistent. Previous meta-analyses have proven that 
nuclear β-catenin overexpression predicts progressive 
disease and unfavorable survival in colorectal cancer [25], 
lung cancer [26, 27], hepatocellular cancer [28], breast 
cancer [29], esophageal cancer [30], and gastric cancer 
[31]. As the prognostic value of β-catenin in pancreatic 
cancer remains controversial, a meta-analysis was needed 
to explore the issue clearly. We pooled the survival data 
of 201 patients with pancreatic cancer from five studies 
(including the present study) and found that aberrant 
β-catenin expression was associated with significantly 
increased mortality risk (HR 3.69, 95% CI 2.30–5.92). 
Our meta-analysis revealed that aberrant β-catenin 
expression could be a predictive factor of poor prognosis 
of pancreatic cancer and that the WNT/β-catenin pathway 
could be a promising treatment target of pancreatic cancer.
Currently, the pancreatic CSC markers include 
CD24, CD44, epithelial cell adhesion molecule (EPCAM) 
[32], c-MET [33], CD133 [34], aldehyde dehydrogenase 
(ALDH) [34], and Hoechst dye exclusion (side 
population) [35]. Combination, but not single, markers 
have been used to identify pancreatic CSCs. CSCs. 
have been proven to preserve the abilities of extensive 
proliferation, self-renewal, multi-lineage differentiation, 
and high tumorigenic potential [36]. A recent study using 
breast cancer biopsy tissues showed that chemotherapy 
led to an increased percentage of CD44+/CD24+ cells, 
consistent with increased clone formation ability [37]. 
CD24+/CD44+ pancreatic cancer cells have a significantly 
higher possibility for forming colonies in vitro and are 
more resistant to irradiation [18]. Survival analysis has 
shown that CD24+/CD44+ expression appears to be 
correlated with poor prognosis [19]. Therefore, CD24 
and CD44 are now widely used for identifying pancreatic 
CSCs [19, 34, 38–40]. It has been well established that 
the WNT/β-catenin signaling pathway is crucial for 
normal stem cell self-renewal and tissue differentiation 
[5], while aberrant WNT/β-catenin signaling pathway 
activation contributes to the maintenance of CSCs 
[8, 41] n. Previously, we found that FH535 induced cell 
cycle arrest and repressed pancreatic cancer cell growth 
in vitro. Presently, we discovered that FH535 decreased 
the population of CD24+/CD44+ pancreatic cancer cells, 
the presumed pancreatic CSCs. Therefore, we speculated 
that the anti-cancer effect of FH535 could also involve 
repressing CSC stemness.
In vivo, cancer cells are surrounded by a complex 
milieu. This cancer cell niche is called the tumor 
microenvironment, and contributes to tumor development 
and metastasis [42]. Angiogenesis has been proven to be a 
crucial influencing factor in the tumor microenvironment; 
it is the foundation of solid tumor growth and metastasis. 
It is well established that all successful tumors must 
undergo neovascularization in order to acquire nutrients 
for continued growth and metastatic spread. Without 
angiogenesis, a solid tumor rarely grows larger than 2 ~ –3 
mm [43]. Research on angiogenesis in general is a major 
focus in biomedicine and has led to the clinical approval 
of several antiangiogenic agents, including thalidomide, 
bevacizumab, sorafenib, sunitinib, pazopanib, 
temsirolimus, and everolimus. Indeed, antiangiogenic 
agents have significantly changed treatment strategies 
for solid tumors, including colorectal cancer, renal cell 
carcinoma, and breast cancer [44]. However, whether 
antiangiogenic therapeutics is a promising strategy for 
treating pancreatic cancer still requires verification.
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In fact, increasing evidence indicates that 
WNT/β-catenin signaling plays a pivotal role in tumor 
angiogenesis by inducing endothelial cell proliferation 
and survival [8, 45]. Studies have revealed that WNT 
overexpression is associated with the expression of genes 
that participate in angiogenesis [46–52]. Furthermore, the 
WNT/β-catenin pathway WNTfrequently cooperates with 
the other angiogenesis-related pathways such as the Notch, 
mitogen-activated protein kinase (MAPK), and nuclear 
factor (NF)-κB pathways [53]. For example, the crosstalk 
Figure 6: FH535 repressed angiogenesis-related genes in pancreatic cancer cells. (A) Microarray analysis of angiogenesis-
related gene expression regulation upon treatment with 20 µM FH535. Up and down arrows, gene expression significantly upregulated or 
downregulated, respectively, by 1.5-fold. (b) Antibody arrays of protein expression of angiogenesis-related genes after FH535 treatment. 
(c) Analysis of antibody array grey levels. *P < 0.05, **P < 0.01, significant differences vs. the respective control groups.
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between the WNT/β-catenin and Notch pathways mediates 
vascular angiogenesis and endothelial specification [54]. 
Secreted Frizzled-related proteina WNT  inhibitor inhibits 
angiogenesis,, by binding WNT protein and antagonizing 
WNT/β-catenin signaling, inversely suggesting that WNT 
protein may be implicated in vascular proliferation [55]. 
Presently, we investigated whether a β-catenin pathway–
targeting therapeutic could exert an antiangiogenic effect 
in pancreatic cancer.
MVD is the best recognized indicator for evaluating 
angiogenesis in solid tumors [56]. Immunostaining of a 
vascular endothelial cell marker such as CD34 is used to 
evaluate MVD [57–60]. MVD is an adverse prognostic 
factor in pancreatic cancer [61] and several other cancers 
[57, 58, 62, 63]. Via CD34 staining, we not only proved 
the association between MVD and the prognosis of 
pancreatic cancer, but also determined the relationship 
between β-catenin and angiogenesis, suggesting that 
the in vivo anti-cancer effect of a β-catenin pathway 
inhibitor could involve an antiangiogenic function 
targeting the tumor microenvironment. The HUVEC tube 
formation assay further showed that FH535 repressed the 
proangiogenic ability of pancreatic cancer cells. Moreover, 
FH535 decreased MVD in pancreatic cancer xenografts. 
Therefore, a β-catenin pathway–targeting therapeutic such 
as FH535 represses the angiogenetic potency of pancreatic 
cancer both in vitro and in vivo.
Abundant angiogenesis regulators and oncogene 
activation are essential for an angiogenesis phenotype 
that supports tumorigenicity [64]. ProteinM and mRNA 
microarrays revealed that FH535 significantly suppressed 
the expression of seven proangiogenic genes: ANGPT2, 
FLT4 (VEGFR3), IFN-γ, PLAUR (uPAR), THPO (TPO), 
TIMP1, and VEGF (VEGFA), at both mRNA and protein 
level. Moreover, the Milliplex assay showed that FH535 
significantly decreased VEGF, IL-6, IL-8, and TNF-α 
levels in culture medium, indicating that the WNT/β-
catenin pathway–targeting strategy represses angiogenesis 
in pancreatic cancer through a mechanism involving 
multiple genes. It is worth noting that FH535 repressed 
VEGF at mRNA expression, and protein expression 
and secretion levels. As VEGF plays a central role in 
angiogenesis, its repression could be critical to the manner 
in which FH535 exerts its antiangiogenic effect.
Taken together with our previous studies, we proved 
that FH535 exerts an anti-cancer effect against pancreatic 
cancer, targeting pancreatic cancer cells by repressing 
cell growth, metastasis, and stemness and targeting the 
tumor microenvironment by inhibiting angiogenesis. 
FH535 exerted its anti-cancer effect against pancreatic 
cancer xenografts in vivo and presents the possibility 
of clinical application. Although targeting the WNT 
signaling pathway in the clinic using small-molecule 
therapeutics or biologics is still in its infancy, several 
therapeutics targeting the WNT/β-catenin pathway have 
already progressed from bench to bedside [65]. For 
example, OMP-18R5 is a fully humanized monoclonal 
anti body that binds to FZD [66]; OMP-54F28 is an Fc 
fusion protein with FZD8 that binds all WNT ligands 
[67]; LGK974 inhibits Porcupine, which enables WNT 
secretion [68, 69]; PRI-724 is a specific CREB-binding 
protein (CBP) and β-catenin antagonist [65]. Clinical trials 
have been initiated to evaluate the effectiveness of these 
therapeutics against pancreatic cancer [65, 67]. Although 
FH535 appears tolerable in mouse models, its on-target 
toxicity (i.e., WNT inhibi tion and effects on intestinal 
stem cells, bone turnover, and hematopoiesis [67]) and 
off-target toxicity (i.e., inhi bition of other members of this 
class of O-acyltransferases or similar enzymes [67]) still 
requires careful evaluation in further investigations.
MAterIAls And MetHods
Ethics statement
This investigation has been conducted in accordance 
with the ethical standards and according to the Declaration 
of Helsinki and according to national and international 
guidelines and has been approved by the First Affiliated 
Hospital of Soochow University Committee on Medical 
Ethics Institutional Review Board.
Patients and tissue samples
The study material was obtained from 58 patients 
with pancreatic cancer whose tissue samples were 
available (mean age 65 years, range 21 ~ 80 years) and 
who were treated during January 2007 to October 2013 
at the First Affiliated Hospital of Soochow University. 
All human tissue samples were obtained and handled in 
accordance with an approved Institutional Review Board 
application (the Committee on Medical Ethics, the First 
Affiliated Hospital of Soochow University). Tumor 
characteristics were obtained from the pathology database 
(Table 1). Patients received systemic therapy according 
to National Comprehensive Cancer Network pancreatic 
cancer clinical practice guidelines and were followed 
regularly for 2 years. Prognostic analyses were performed 
regarding OS.
Meta-analysis
We carried out a search of the PubMed database 
using the following terms and all possible combinations: 
“pancreatic cancer”, “pancreatic carcinoma”, “pancreatic 
neoplasm”, “beta-catenin”, “β-catenin” and “CTNNB1”. 
The search duration was from November 1985 to 
November 2015; no lower date limit was used. The citation 
lists associated with the studies were used to identify 
additional eligible studies. Reviews and bibliographies 
were also manually inspected to find related articles. The 
inclusion criteria, exclusion criteria, and statistical analysis 
are presented in the Supplementary Methods.
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Cell lines and culture conditions
The human pancreatic cancer cell lines PANC-1 
and CFPAC-1, and HUVECs, were purchased from 
American Type Culture Collection and maintained in a 
humidified incubator with a 5% CO2–95% air atmosphere 
at 37°C. PANC-1 and CFPAC-1 cells were maintained 
in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% FBS (Gibco), 100 units/mL 
penicillin, and 100 μg/mL streptomycin. HUVECs were 
maintained in DMEM supplemented with 10% FBS, 2 
mmol/L glutamine, 0.1 mmol/L hypoxanthine, 0.4 mmol/L 
aminopterin, 16 mmol/L thymidine, 100 units/mL 
penicillin, and 100 μg/mL streptomycin.
Immunohistochemistry
All resection specimens were fixed in 10% buffered 
formalin and paraffin-embedded by routine processing. 
Sections were cut at 4-μm thickness, heated at 60°C for 
30 min, then deparaffinized and hydrated through a series 
of xylene and alcohol baths. The slides were microwaved 
with antigen retrieval solution (citrate buffer, pH 6.0, 
containing 0.3% trisodium citrate and 0.04% citric acid) 
for 5 min. After replenishment of this solution, the slides 
were microwaved again for 5 min and then allowed to 
cool for 20 min. The sections were then rinsed in PBS and 
immersed in 3% H2O2 for 15 min to block the endogenous 
peroxidase. Thereafter, the sections were incubated with 
10% bovine serum albumin at room temperature for 1 h 
to block nonspecific antibodies. Immunohistochemical 
staining was performed with mouse anti–β-catenin 
antibody (sc59737; Santa Cruz Biotechnology), mouse 
anti–Ki-67 antibody (GM724029; GeneTech, Shanghai, 
China), or rabbit anti-CD34 antibody (ab81289; Abcam, 
London, UK) at room temperature for 2 h. After incubation 
with the corresponding secondary antibodies for 20 min, 
the bound complex was visualized using a SuperPicture 
Polymer Detection Kit (No. 87-8963; Invitrogen).
Evaluation of immunostaining
Two independent researchers evaluated the 
immunostaining results. All analyses were performed 
blind with respect to the clinical outcomes. Briefly, 
the five most representative high-power fields (×400 
magnification) per slide were selected. To evaluate 
the validity of the analysis, the area measurement and 
counting were repeated 4 weeks later.
To grade the immunohistochemical findings for 
β-catenin, sections were scored based on the extent and 
intensity of staining; membranous and cytoplasmic 
staining were assessed separately [10]. The scoring 
system is presented in the Supplementary Methods. Ki-67 
immunoreactivity was expressed as the mean percentage 
of tumor cells with the highest nuclear labeling after 
manual counting of 20 hotspot areas. Endothelial cells 
were marked with anti-CD34 antibody and subjected 
to MVD and angiogenesis vascularity evaluation [70] 
(Supplementary Methods).
Nude mouse tumor xenograft model and 
treatment
Four-week-old female BALB/c athymic nude 
mice were purchased from Shanghai SLAC Laboratory 
Animal Co. Ltd (Shanghai, China) and received humane 
care according to the Soochow University Institutional 
Animal Care and Treatment Committee. PANC-1 cells 
stably expressing firefly luciferase were injected into 
the left flanks of the mice in a total volume of 100 μL 
(0.5 × 107 cells), and the mice were randomly assigned 
to a dimethyl sulfoxide (DMSO) [intraperitoneally 
injected with 100 μL DMSO/DMEM (1:1)] or FH535 
group [intraperitoneally injected with 25 mg/kg FH535 
(Millipore) dissolved in 100 μL DMSO/DMEM (1:1)]. 
Treatment was conducted every 2 days for 20 days; tumor 
volume was measured with a caliper using the formula: 
volume = length × width2/2. At the end of the experiment, 
the mice were anaesthetized and given D-luciferin in 
PBS. Twenty minutes after the injection, bioluminescence 
was imaged with a charge-coupled device camera (IVIS; 
Lumina II, PerkinElmer). Then, the tumor tissue was 
stripped and formalin-fixed, paraffin-embedded, cut into 
4-μm sections, and immunohistochemically stained.
Microarray assay
Total RNA from each sample was amplified and 
transcribed into fluorescent cRNA according to Agilent 
Technologies’ Quick Amp Labeling protocol (version 
5.7). The labeled cRNAs were hybridized onto a Whole 
Human Genome Oligo Microarray (4x44K; Agilent 
Technologies). After washing the slides, the arrays were 
scanned using an Agilent Technologies Scanner G2505C. 
Agilent Technologies Feature Extraction software 
(version 11.0.1.1) was used to analyze the acquired 
array images. Quantile normalization and subsequent 
data processing were performed using the GeneSpring 
GX v11.5.1 software package (Agilent Technologies). 
Differentially expressed genes were identified through 
fold change filtering. The selection criterion was 
> 1.5-fold difference in expression (upregulated expression 
> 1.5-fold; downregulated expression < 0.67-fold). GO 
analysis (Supplementary Methods) was used to determine 
the roles played by the differentially expressed genes in 
these biological GO terms.
Real-time PCR
Total RNA was extracted using TRIzol 
(Invitrogen) according to the manufacturer’s protocol. 
After spectrophotometric quantification, 1 μg total 
RNA in a final volume of 20 μL was used for reverse 
Oncotarget47158www.impactjournals.com/oncotarget
transcription with a PrimeScript RT Reagent Kit (TaKaRa, 
Otsu, Shiga, Japan) according to the manufacturer’s 
protocol. Aliquots of cDNA corresponding to equal 
amounts of RNA were used for mRNA quantification 
by real-time PCR using a LightCycler 96 Real-time 
Quantitative PCR Detection System (Roche). The 
reaction system (25 μL) contained the corresponding 
cDNA, forward and reverse primers, and SYBR Green 
PCR master mix (Roche). All data were analyzed using 
B2M gene expression as the internal standard. The 
specific primers were as follows: (1) CD24, forward, 
5′-CAGGGCAATGATGAATGAGAAT-3′, reverse, 5′-CC 
TGGGCGACAAAGTGAGA-3′, product, 233 bp; (2) 
CD44, forward, 5′-GTGATGGCACCCGCTATGTC-3′, 
reverse, 5′-AACCTCCTGAAGTGCTGCTCC-3′, product, 
129 bp; (3) B2M, forward, 5′-TCAAGAAGGTG 
GTGAAGCAG-3′, reverse, 5′-AAGGTGGAGGAGT 
GGGTGTC-3′, product, 112 bp.
Evaluation of protein expression
The expression levels of CD24 and CD44 
protein in pancreatic cancer cells was measured 
by flow cytometry. Following treatment, the cells 
were harvested, fixed with 4% paraformaldehyde, 
and permeabilized using 0.1% Triton X-100. After 
washing thrice with PBS, the cells were incu-
bated with anti-CD24 (fluorescein isothiocyanate 
[FITC]-conjugated; Santa Cruz Biotechnology) and 
anti-CD44 (phycoerythrin [PE]-conjugated, Santa 
Cruz Biotechnology) antibodies for 30 min at 4°C. 
Subsequently, the cells were analyzed using a Beckman 
Coulter FC500 flow cytometer.
Stemness evaluation of pancreatic cancer cells
The cells were harvested, washed twice with 2% 
FBS/PBS solution, and resuspended in 100 μL 2% FBS/
PBS before incubating with FITC-conjugated anti-CD24 
and PE-conjugated anti-CD44 antibodies for 30 minutes 
at 4°C. The cells were then washed twice with 2% FBS/
PBS solution and resuspended in 500 μL 2% FBS/PBS 
prior to reading on a Beckman Coulter FC500 flow 
cytometer.
ChIP-Seq data analysis
β-Catenin ChIP-Seq data  (SRX017112) were 
obtained from the Sequence Read Archive database 
(http://www.ncbi.nlm.nih.gov/sra/SRX017112). The raw 
sequencing data were evaluated by FAST-QC, including 
quality distribution of nucleotides, position-specific 
sequencing quality, GC content, proportion of PCR 
duplication, and Wmer frequency. We used Burrows-
Wheeler Aligner, a backward search–based read alignment 
package, with Burrows–Wheeler transform for genome-
wide mapping. Peak calling was performed comparing 
ChIP material to input using MACS14 (1.4.0rc2); binding 
regions were ranked based on sequencing tag enrichment 
by comparing each ChIP library to the control. A threshold 
P-value < 0.0001 was applied; alignment was carried 
out using FastQC with hg19_GRCh37 as the build. 
Motifs were discovered using XXmotif (http://xxmotif.
genzentrum.lmu.de), a de novo motif discovery method 
that directly optimizes the statistical significance of 
position weight matrices [71, 72].
Tube formation assay for angiogenesis evaluation
For basement membrane reconstitution, Matrigel 
(BD Biosciences) was diluted 2-fold with cold DMEM 
(without FBS) and added to 96-well plates at 4°C. 
The plates were incubated for 2 h in a 37°C cell 
culture incubator to allow the Matrigel to solidify. 
Carboxyfluorescein diacetate succinimidyl ester 
(Beyotime, Shanghai, China)-labeled HUVECs were 
trypsinized, counted, resuspended in basal medium, and 
added on top of the reconstructed basement membrane 
(5 × 104 cells/well). After 4~12 h, the formed networks 
were photographed and analyzed using Image-Pro Plus 
(Media Cybernetics) to calculate the area of the network. 
Endotubes were quantified by counting nine random 
fields/sample under a microscope (×40 magnification).
Milliplex assay
A multiplex biometric immunoassay containing 
fluorescent-dyed microbeads (Cat. No. HCYTOMAG-60 
K; Millipore) was used for measuring VEGF, IL-6, IL-8, 
and TNF-α levels in culture medium. Mean fluorescence 
intensity was calculated by Luminex Technology 
(Bio-Plex Workstation; Bio-Rad Laboratories). Data 
were analyzed using Milliplex® Analyst 5.1 (Bio-Rad 
Laboratories).
Angiogenesis antibody array
Proteins in the cell samples were biotinylated, and 
spin-filtered to remove excess biotin. The biotinylated 
samples were dialyzed with PBS and added to RayBio 
Human Angiogenesis Antibody Array membranes 
(RayBiotech, Norcross, Ga). Biotinylated proteins 
captured by the membrane-bound antibodies were detected 
by incubation with horseradish peroxidase–streptavidin 
and analyzed using a chemiluminescence imaging system 
(RayBiotech). Normalization was performed using the 
signal of internal controls on each protein array chip. 
Quality control was performed by removing proteins 
detected below the raw signal intensity of 50, which 
was twice the maximum intensity of the negative control 
probes. Significance testing was performed by t-test; 
fold-change was cut-off at 1.5.
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Statistical analysis
Statistical analysis was performed using SPSS 
16.0 software (SPSS Inc.). Chi square tests were used for 
comparing Ki-67, MVD, and β-catenin. The correlations 
between MVD and Ki-67 were analyzed using Spearman’s 
rank test. Kaplan–Meier curves were constructed to 
analyze survival data; statistical analysis was carried out 
using log-rank testing. OS was defined as the time from 
the beginning of surgery to death from any cause or the 
last date of follow-up. The relationships between nuclear 
β-catenin or MVD and tumor characteristics or clinical 
outcomes were examined and assessed using univariate 
analysis. For gene expression data, statistical analyses 
were carried out with unpaired Student’s t-tests. All data 
are presented as the mean ± SD. Statistical significance 
was determined at P < 0.05; all tests were two-sided.
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